Reviva Pharmaceuticals Holdings, Inc. announced that 446 participants have completed their long-term open-label extension (OLE) trial for brilaroxazine, with 156 participants receiving one year of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback